Alnylam Pharmace. sell Biotechhunter
Start price
31.07.20
/
50%
€125.52
Target price
06.08.20
-
Performance (%)
-3.39%
End price
06.08.20
€121.26
Summary
This prediction ended on 06.08.20 with a price of €121.26. With a performance of -3.39%, the SELL prediction for Alnylam Pharmace. by Biotechhunter was down slightly. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -1.828% | -1.828% | -50.133% | 11.477% |
| iShares Core DAX® | 1.001% | 4.831% | 8.149% | 62.596% |
| iShares Nasdaq 100 | 2.702% | -1.720% | 26.924% | 88.135% |
| iShares Nikkei 225® | 3.519% | -3.506% | 48.064% | 78.113% |
| iShares S&P 500 | 1.766% | 1.273% | 23.577% | 70.466% |